Portal de Periódicos da CAPES

Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy

2002; Lippincott Williams & Wilkins; Volume: 167; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(05)64985-3

1527-3792

Alfredo Berruti, Luigi Dogliotti, Carlo Terrone, Stefania Cerutti, Giancarlo Isaia, R. Tarabuzzi, Giuseppe Reimondo, Mauro Mari, P Ardissone, Stefano De Luca, G. Fasolis, Dario Fontana, S. Rocca Rossétti, Alberto Angeli,

Prostate Cancer Treatment and Research

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jun 2002Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy ALFREDO BERRUTI, LUIGI DOGLIOTTI, CARLO TERRONE, STEFANIA CERUTTI, GIANCARLO ISAIA, ROBERTO TARABUZZI, GIUSEPPE REIMONDO, MAURO MARI, PAOLA ARDISSONE, STEFANO DE LUCA, GIUSEPPE FASOLIS, DARIO FONTANA, SALVATORE ROCCA ROSSETTI, ALBERTO ANGELI, and for the GRUPPO ONCO UROLOGICO PIEMONTESE (G.O.U.P.) RETE ONCOLOGICA PIEMONTESE ALFREDO BERRUTIALFREDO BERRUTI , LUIGI DOGLIOTTILUIGI DOGLIOTTI , CARLO TERRONECARLO TERRONE , STEFANIA CERUTTISTEFANIA CERUTTI , GIANCARLO ISAIAGIANCARLO ISAIA , ROBERTO TARABUZZIROBERTO TARABUZZI , GIUSEPPE REIMONDOGIUSEPPE REIMONDO , MAURO MARIMAURO MARI , PAOLA ARDISSONEPAOLA ARDISSONE , STEFANO DE LUCASTEFANO DE LUCA , GIUSEPPE FASOLISGIUSEPPE FASOLIS , DARIO FONTANADARIO FONTANA , SALVATORE ROCCA ROSSETTISALVATORE ROCCA ROSSETTI , ALBERTO ANGELIALBERTO ANGELI , and for the GRUPPO ONCO UROLOGICO PIEMONTESE (G.O.U.P.) RETE ONCOLOGICA PIEMONTESE View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64985-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We characterize the consequences of androgen deprivation therapy on body composition in elderly men. Materials and Methods: Using a dual energy x-ray absorptiometry instrument, we determined the changes in bone mineral density, bone mineral content, fat body mass and lean body mass in 35 patients with prostate cancer without bone metastases who received luteinizing hormone releasing hormone analogue for 12 months. Results: At baseline conditions 46% of cases were classified as osteopenic and 14% as osteoporotic at the lumbar spine and 40% were osteopenic and 4% osteoporotic at the hip. Androgen deprivation significantly decreased bone mineral density either at the lumbar spine (mean gm./cm.2 [SD] 1.00 [0.194], 0.986 [0.172] and 0.977 [0.182] at baseline, and 6 and 12 months, respectively, p <0.002) or the hip (0.929 [0.136], 0.926 [0.144] and 0.923 [0.138], p <0.03). A more than 2% decrease in bone mineral density was found at the lumbar spine in 19 men (54.3%) and at the hip in 15 (42.9%). Bone mineral content paralleled the bone mineral density pattern. Lean body mass decreased (mean gm. [SD] 50,287 [6,656], 49,296 [6,554] and 49,327 [6,345], p <0.003), whereas fat body mass consistently increased (18,115 [6,209], 20,724 [6,029] and 21,604 [5,923] p <0.001). Conclusions: Serial bone densitometry evaluation during androgen deprivation therapy may allow the detection of patients with prostate cancer at risk for osteoporotic fractures, that is those with osteopenia or osteoporosis at baseline and fast bone loss. The change in body composition may predispose patients to accidental falls, thus increasing the risk of bone fracture. References 1 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 178. Google Scholar 2 : Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol1998; 159: 1993. Link, Google Scholar 3 : Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. Am J Med1993; 95: 22S. Google Scholar 4 : Potential side effects of endocrine treatment of long duration in prostate cancer. Prostate2000; 10: 38. Google Scholar 5 : Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab1989; 69: 523. Google Scholar 6 : Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int1994; 54: 327. Google Scholar 7 : Osteoporosis after orchiectomy for prostate cancer. J Urol1997; 157: 439. Link, Google Scholar 8 : Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol1995; 154: 535. Link, Google Scholar 9 : Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer1997; 79: 545. Crossref, Medline, Google Scholar 10 : Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int2000; 86: 449. Google Scholar 11 : Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology1999; 54: 607. Crossref, Medline, Google Scholar 12 : Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology2001; 57: 127. Google Scholar 13 : Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogen. Calcif Tissue Int1995; 57: 97. Google Scholar 14 : The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer1998; 83: 1561. Google Scholar 15 : Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999; 161: 1219. Link, Google Scholar 16 : Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc Am Soc Clin Oncol1999; 18: 314a. Google Scholar 17 : Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol2000; 163: 181. Link, Google Scholar 18 : Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab1998; 83: 1886. Google Scholar 19 : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA1997; 277: 1445. Crossref, Medline, Google Scholar 20 : Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake. J Am Diet Assoc1989; 89: 1484. Google Scholar 21 : Risk factors for longitudinal bone loss in elderly men and women: the Framingham osteoporosis study. J Bone Miner Res2000; 15: 710. Google Scholar 22 : Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med1996; 156: 1399. Google Scholar 23 : Incidence of skeletal complications in bone metastatic prostate cancer patients with hormone refractory disease. Predictive role of bone resorption and formation markers evaluated at baseline. J Urol2000; 164: 1248. Abstract, Google Scholar 24 : Dual energy x-ray absorptiometry in the evaluation of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep2000; 7: 777. Google Scholar 25 : Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol2000; 163: 1743. Link, Google Scholar From the Department of Clinical and Biological Sciences, University of Torino at San Luigi Hospital, Orbassano, Medical Oncology, Internal Medicine, Urology, Department of Internal Medicine and Urology, University of Torino at San Giovanni Battista Hospital, Torino, and Urology San Lazzaro Hospital, Alba, Italy© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySaylor P and Smith M (2018) Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 189, NO. 1S, (S34-S44), Online publication date: 1-Jan-2013.Morgans A, Hancock M, Barnette K, Steiner M, Morton R and Smith M (2012) Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 187, NO. 3, (889-893), Online publication date: 1-Mar-2012.Saylor P, Morton R, Hancock M, Barnette K, Steiner M and Smith M (2011) Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 186, NO. 2, (482-486), Online publication date: 1-Aug-2011.Saylor P, Kaufman D, Michaelson M, Lee R and Smith M (2010) Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 183, NO. 6, (2200-2205), Online publication date: 1-Jun-2010.Saylor P and Smith M (2009) Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 181, NO. 5, (1998-2008), Online publication date: 1-May-2009.Israeli R, Ryan C and Jung L (2007) Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation TherapyJournal of Urology, VOL. 179, NO. 2, (414-423), Online publication date: 1-Feb-2008.Krupski T, Foley K, Baser O, Long S, Macarios D and Litwin M (2007) Health Care Cost Associated With Prostate Cancer, Androgen Deprivation Therapy and Bone ComplicationsJournal of Urology, VOL. 178, NO. 4, (1423-1428), Online publication date: 1-Oct-2007.Eastham J (2018) Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 177, NO. 1, (17-24), Online publication date: 1-Jan-2007.Srinivas S and Colocci N (2018) Bone Related Events in High Risk Prostate CancerJournal of Urology, VOL. 176, NO. 6S, (S50-S54), Online publication date: 1-Dec-2006.Morote J, Orsola A, Abascal J, Planas J, Trilla E, Raventos C, Cecchini L, Encabo G and Reventos J (2018) Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen SuppressionJournal of Urology, VOL. 175, NO. 5, (1679-1683), Online publication date: 1-May-2006.SMITH M (2018) OSTEOPOROSIS AND OBESITY IN MEN RECEIVING HORMONE THERAPY FOR PROSTATE CANCERJournal of Urology, VOL. 172, NO. 5S, (S52-S57), Online publication date: 1-Nov-2004.DIAMOND T, BUCCI J, KERSLEY J, ASLAN P, LYNCH W and BRYANT C (2018) OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, VOL. 172, NO. 2, (529-532), Online publication date: 1-Aug-2004.SIEBER P, KEILLER D, KAHNOSKI R, GALLO J and MCFADDEN S (2018) BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCERJournal of Urology, VOL. 171, NO. 6 Part 1, (2272-2276), Online publication date: 1-Jun-2004. Volume 167Issue 6June 2002Page: 2361-2367 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsandrogensosteoporosisbody compositionprostatic neoplasmsMetricsAuthor Information ALFREDO BERRUTI More articles by this author LUIGI DOGLIOTTI More articles by this author CARLO TERRONE More articles by this author STEFANIA CERUTTI More articles by this author GIANCARLO ISAIA More articles by this author ROBERTO TARABUZZI More articles by this author GIUSEPPE REIMONDO More articles by this author MAURO MARI More articles by this author PAOLA ARDISSONE More articles by this author STEFANO DE LUCA More articles by this author GIUSEPPE FASOLIS More articles by this author DARIO FONTANA More articles by this author SALVATORE ROCCA ROSSETTI More articles by this author ALBERTO ANGELI More articles by this author for the GRUPPO ONCO UROLOGICO PIEMONTESE (G.O.U.P.) RETE ONCOLOGICA PIEMONTESE More articles by this author Expand All Advertisement PDF downloadLoading ...